Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diasorin SpACHIX:DIAM -1.71%78 EV-to-EBITDA is 11.68 as of Jul. 14, 2026, which is 43% below its 10-year median of 20.58. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €90.24 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 118 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 61.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Diasorin SpA's enterprise value is €4,013 Mil.
Diasorin SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €344 Mil. Therefore, Diasorin SpA's EV-to-EBITDA for today is 11.68.
The historical rank and industry rank for Diasorin SpA's EV-to-EBITDA or its related term are showing as below:
CHIX:DIAm'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.27 Med: 20.58 Max: 51.24
Current: 11.68
During the past 13 years, the highest EV-to-EBITDA of Diasorin SpA was 51.24. The lowest was 9.27. And the median was 20.58.
CHIX:DIAm's EV-to-EBITDA is ranked better than 61.86% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.825
vs CHIX:DIAm: 11.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Diasorin SpA (CHIX:DIAm) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diasorin SpA's PE Ratio (TTM) for today is calculated as:
Diasorin SpA's share price for today is €69.54.
Diasorin SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.642.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Diasorin SpA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIAM vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's EV-to-EBITDA falls into.
Diasorin SpA's current Enterprise Value is €4,013 Mil.
Diasorin SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €344 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (CHIX:DIAM) has a EV-to-EBITDA of 11.68 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diasorin SpA. This is 43% below median its historical median of 20.58. Over the past decade, Diasorin SpA's EV-to-EBITDA has ranged from 9.27 to 51.24. According to the industry distribution chart, Diasorin SpA ranks #45 out of 118 companies in the Medical Diagnostics & Research industry, placing it in the top 38.1%.
Is Diasorin SpA's EV-to-EBITDA too high?
Diasorin SpA's current EV-to-EBITDA of 11.68 is 43% below median its 10-year median of 20.58. Over the past 10 years, this metric has ranged from a low of 9.27 to a high of 51.24. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.83. Diasorin SpA's value of 11.68 is 21.2% below this industry median. Based on the distribution chart, Diasorin SpA ranks #45 out of 118 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #45 out of 118 companies for EV-to-EBITDA. This puts Diasorin SpA in the upper half of its industry. The industry median EV-to-EBITDA is 14.83. Diasorin SpA's value of 11.68 is 21.2% below this benchmark. Historically, Diasorin SpA's own EV-to-EBITDA has ranged from 9.27 to 51.24 over the past decade. While the company's 10-year median is 20.58 vs. the industry median of 14.83, Diasorin SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.83, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current EV-to-EBITDA of 11.68 is 21.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diasorin SpA. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current EV-to-EBITDA is 11.68, which is 43% below median its own 10-year median of 20.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.24, compared to a current price of €69.54 — trading 22.9% below its estimated fair value. The current EV-to-EBITDA is 11.68, which is 43% below median its 10-year median of 20.58 and 21.2% below the Medical Diagnostics & Research industry median of 14.83. Diasorin SpA's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current EV-to-EBITDA is 11.68 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €69.54 is trading 22.9% below its estimated GF Value™ of €90.24.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for CHIX:DIAM:
EV-to-EBITDA: 11.68 (43% below median its 10-year median of 20.58)
GF Value™: €90.24 vs. price of €69.54 (22.9% below fair value)
Industry Position: 21.2% below the Medical Diagnostics & Research median (#45 of 118)
No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score
Get the complete analysis for CHIX:DIAM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIAM has been successfully added to your 
